Association of step counts over time with the risk of chronic disease in the All of Us Research Program - PubMed
. 2022 Nov;28(11):2301-2308.
doi: 10.1038/s41591-022-02012-w. Epub 2022 Oct 10.
Jeffrey Annis 1 , Shi Huang 2 , Joshua A Beckman 3 , Francis Ratsimbazafy 1 , Kayla Marginean 1 , Robert Carroll 4 , Karthik Natarajan 5 , Frank E Harrell 2 , Dan M Roden 6 , Paul Harris 7 , Evan L Brittain 8
Affiliations
- PMID: 36216933
- PMCID: PMC9671804
- DOI: 10.1038/s41591-022-02012-w
Association of step counts over time with the risk of chronic disease in the All of Us Research Program
Hiral Master et al. Nat Med. 2022 Nov.
Erratum in
-
Master H, Annis J, Huang S, Beckman JA, Ratsimbazafy F, Marginean K, Carroll R, Natarajan K, Harrell FE, Roden DM, Harris P, Brittain EL. Master H, et al. Nat Med. 2023 Dec;29(12):3270. doi: 10.1038/s41591-023-02313-8. Nat Med. 2023. PMID: 37046000 Free PMC article. No abstract available.
Abstract
The association between physical activity and human disease has not been examined using commercial devices linked to electronic health records. Using the electronic health records data from the All of Us Research Program, we show that step count volumes as captured by participants' own Fitbit devices were associated with risk of chronic disease across the entire human phenome. Of the 6,042 participants included in the study, 73% were female, 84% were white and 71% had a college degree, and participants had a median age of 56.7 (interquartile range 41.5-67.6) years and body mass index of 28.1 (24.3-32.9) kg m-2. Participants walked a median of 7,731.3 (5,866.8-9,826.8) steps per day over the median activity monitoring period of 4.0 (2.2-5.6) years with a total of 5.9 million person-days of monitoring. The relationship between steps per day and incident disease was inverse and linear for obesity (n = 368), sleep apnea (n = 348), gastroesophageal reflux disease (n = 432) and major depressive disorder (n = 467), with values above 8,200 daily steps associated with protection from incident disease. The relationships with incident diabetes (n = 156) and hypertension (n = 482) were nonlinear with no further risk reduction above 8,000-9,000 steps. Although validation in a more diverse sample is needed, these findings provide a real-world evidence-base for clinical guidance regarding activity levels that are necessary to reduce disease risk.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests. The sponsor, All of Us Research Program, as well as Fitbit, had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Figures

a, Negative log base-10 P values for each phecode are plotted as a function of the OR from the corresponding logistic regression with average daily step count. EF, ejection fraction; NOS, not otherwise specified. OR is reported per 1,000 step count increase, as adjusted for age, race and sex. All phecodes occurred after 6 months of Fitbit monitoring and not before. Horizontal red line indicates the Bonferroni corrected α level of 3.1856 × 10–5, accounting for all phecodes used. Vertical line is OR = 1. b, OR and 95% CI to quantify the association of increasing daily step counts with selected outcomes, that is type 2 diabetes mellitus (T2DM) with (w/) neurological manifestation (manif.) (sample size, N = 5,976), sleep apnea (N = 5,699), obstructive sleep apnea (N = 5,518), obesity (N = 5,267), major depressive disorder (N = 5,370), GERD (N = 5,091) and essential hypertension (N = 4,897). The points represent OR and error bars represent 95% CI. The values toward the right of the figure represent OR (95% CI) values in text format. All models were adjusted for age, race and sex.

a, Cox models were used to compute HRs as a function of average daily step count. Median step counts of 8,160 (diabetes), 8,290 (essential hypertension), 8,260 (GERD), 8,210 (major depressive disorder), 8,280 (obesity) and 8,220 (sleep apnea) were used as reference. b, Cumulative incidence by year for each outcome as a function of average daily step count. Shaded area represents 95% CI. All the Cox models were adjusted for age, race, sex, CAD, cancer, BMI, systolic blood pressure, education level, smoking and alcohol use.

a, Cox models were used to compute HR for obesity (outcome) as a function of average daily step count as stratified by BMI of 25–29 kg m–2. A median step count of 8,594 steps was used as reference. b, Cumulative incidence by year as a function of average daily step count and as stratified by BMI of 25–29 kg m–2. The model is identical to models previously described except BMI was allowed to interact linearly with the average daily step count.

The flow diagram graphically depicts the steps that were utilized to derive the analytical sample that met the inclusion and exclusion criteria. EHR, electronic health records.

The bar chart depicts number of participants who reported having multimorbidity among 6 conditions, i.e. diabetes, hypertension, gastroesophageal reflux disease, major depressive disorder, obesity and sleep apnea.

Relation between daily steps counts and incident risk of chronic diseases. a: Adjusted Hazard ratio on log-transformed scale as a function average daily steps for each select outcome. b: Log relative hazard as a function of average steps for each selected outcome. All the models were adjusted for age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Shaded area represents 95%confidence interval.

Trajectory of average daily step counts (mean and 95% confidence interval) among participants who did (status = True) and did not (status = False) develop each of the conditions, that is, diabetes (Sample Size (N) = 5124), essential hypertension (N = 4437), GERD (N = 4613), major depressive disorders (N = 4884), obesity (N = 4774) and sleep apnea (N = 4922) that were examined in Cox Models. Indentation (>) represents the break in y-axis.

Relation between daily step counts and incident risk of actinic keratosis and carpal tunnel syndrome. a: Adjusted Hazard ratios as a function of average daily step count. All the models were adjusted for age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Reference for steps was the median steps count at 8,064 steps. b: Cumulative incidence by year as a function of average daily step count for each selected outcome. Shaded area represents 95%confidence interval.

Incidence rates (number of events shown in brackets) for each diagnosis as a function of step counts and bout cadence (step intensity) quartiles. Incidence rates is number of cases per 1000 people for each diagnosis as a function of step and bout cadence quartiles. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days. Step quartile intervals (thous.) are as follows: 1: [549,5.87]; 2: [5.87,7.73]; 3: [7.73,9.83]; 4: [9.83,33.6]. Bout cadence quartiles are as follows: 1: [68.1,83.6]; 2: [83.6,88.7]; 3: [88.7,94.3]; 4: [94.3,158].

Probability density plot examining the relation between step counts and bout cadence (step intensity) on continuous spectrum in participants who developed (represented as TRUE) vs. did not develop the condition (represented as FALSE). Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days.

Incidence rates (number of events shown in brackets) for each diagnosis as a function of step counts and bout cadence (step intensity) quartiles. Incidence rates is number of cases per 1000 people for each diagnosis as a function of step and bout cadence quartiles. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥100 steps/minute across all the valid days. Step quartile intervals (thous.) are as follows: 1: [549,5.87]; 2: [5.87,7.73]; 3: [7.73,9.83]; 4: [9.83,33.6]. Bout cadence quartiles are as follows: 1: [102,109]; 2: [109,111]; 3: [111,114]; 4: [113,207].

Relation between daily steps counts and incident risk of chronic diseases. A: Hazard ratio as a function of average daily steps in thousands for each outcome. B: Cumulative incidence as a function of average daily steps for each selected outcome by year. Results of Cox model with average daily bout cadence (step intensity) as covariate, in addition to other covariates: age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days. Shaded area represents 95%confidence interval.

Relation between daily bout cadence (step intensity) and incident risk of chronic diseases. a: Hazard ratio as a function of average daily bout cadence (step intensity) for each outcome. b: Cumulative incidence as a function of average daily bout cadence for each selected outcome by year. Results of Cox model with average daily steps, average daily bout cadence addition to other covariates: age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days. Shaded area represents 95%confidence interval.
Comment in
-
Reducing chronic disease may just be a walk in the park.
Shapiro B, Forger DB. Shapiro B, et al. Cell Rep Med. 2022 Dec 20;3(12):100874. doi: 10.1016/j.xcrm.2022.100874. Cell Rep Med. 2022. PMID: 36543094 Free PMC article.
Similar articles
-
Beagle AJ, Tison GH, Aschbacher K, Olgin JE, Marcus GM, Pletcher MJ. Beagle AJ, et al. JMIR Mhealth Uhealth. 2020 Dec 29;8(12):e22090. doi: 10.2196/22090. JMIR Mhealth Uhealth. 2020. PMID: 33372896 Free PMC article.
-
Perry AS, Annis JS, Master H, Nayor M, Hughes A, Kouame A, Natarajan K, Marginean K, Murthy V, Roden DM, Harris PA, Shah R, Brittain EL. Perry AS, et al. J Clin Endocrinol Metab. 2023 Apr 13;108(5):1101-1109. doi: 10.1210/clinem/dgac695. J Clin Endocrinol Metab. 2023. PMID: 36458881 Free PMC article.
-
Arch ES, Sions JM, Horne J, Bodt BA. Arch ES, et al. Prosthet Orthot Int. 2018 Oct;42(5):518-526. doi: 10.1177/0309364618767138. Epub 2018 Apr 6. Prosthet Orthot Int. 2018. PMID: 29623810
-
Systematic review of the validity and reliability of consumer-wearable activity trackers.
Evenson KR, Goto MM, Furberg RD. Evenson KR, et al. Int J Behav Nutr Phys Act. 2015 Dec 18;12:159. doi: 10.1186/s12966-015-0314-1. Int J Behav Nutr Phys Act. 2015. PMID: 26684758 Free PMC article. Review.
-
Hodkinson A, Kontopantelis E, Zghebi SS, Grigoroglou C, McMillan B, Marwijk HV, Bower P, Tsimpida D, Emery CF, Burge MR, Esmiol H, Cupples ME, Tully MA, Dasgupta K, Daskalopoulou SS, Cooke AB, Fayehun AF, Houle J, Poirier P, Yates T, Henson J, Anderson DR, Grey EB, Panagioti M. Hodkinson A, et al. J Med Internet Res. 2022 Aug 30;24(8):e36337. doi: 10.2196/36337. J Med Internet Res. 2022. PMID: 36040779 Free PMC article. Review.
Cited by
-
Zeng C, Schlueter DJ, Tran TC, Babbar A, Cassini T, Bastarache LA, Denny JC. Zeng C, et al. J Am Med Inform Assoc. 2024 Apr 3;31(4):846-854. doi: 10.1093/jamia/ocad260. J Am Med Inform Assoc. 2024. PMID: 38263490 Free PMC article.
-
Understanding activity and physiology at scale: The Apple Heart & Movement Study.
Truslow J, Spillane A, Lin H, Cyr K, Ullal A, Arnold E, Huang R, Rhodes L, Block J, Stark J, Kretlow J, Beatty AL, Werdich A, Bankar D, Bianchi M, Shapiro I, Villalpando J, Ravindran S, Mance I, Phillips A, Earl J, Deo RC, Desai SA, MacRae CA. Truslow J, et al. NPJ Digit Med. 2024 Sep 10;7(1):242. doi: 10.1038/s41746-024-01187-5. NPJ Digit Med. 2024. PMID: 39256546 Free PMC article.
-
Xu Q, Kim Y, Chung K, Schulz P, Gottlieb A. Xu Q, et al. JMIR Form Res. 2024 Jul 18;8:e55575. doi: 10.2196/55575. JMIR Form Res. 2024. PMID: 39024003 Free PMC article.
-
Zheng NS, Annis J, Master H, Han L, Gleichauf K, Ching JH, Nasser M, Coleman P, Desine S, Ruderfer DM, Hernandez J, Schneider LD, Brittain EL. Zheng NS, et al. Nat Med. 2024 Sep;30(9):2648-2656. doi: 10.1038/s41591-024-03155-8. Epub 2024 Jul 19. Nat Med. 2024. PMID: 39030265 Free PMC article.
-
Hurwitz E, Meltzer-Brody S, Butzin-Dozier Z, Patel RC, Elhadad N, Haendel MA. Hurwitz E, et al. medRxiv [Preprint]. 2024 Oct 7:2024.10.07.24315026. doi: 10.1101/2024.10.07.24315026. medRxiv. 2024. PMID: 39417142 Free PMC article. Preprint.
References
Publication types
MeSH terms
Grants and funding
- OT2 OD026556/OD/NIH HHS/United States
- U2C OD023196/OD/NIH HHS/United States
- OT2 OD025315/OD/NIH HHS/United States
- OT2 OD026551/OD/NIH HHS/United States
- U24 OD023121/OD/NIH HHS/United States
- OT2 OD026552/OD/NIH HHS/United States
- OT2 OD025337/OD/NIH HHS/United States
- R01 HL146588/HL/NHLBI NIH HHS/United States
- OT2 OD025277/OD/NIH HHS/United States
- OT2 OD026555/OD/NIH HHS/United States
- OT2 OD026550/OD/NIH HHS/United States
- OT2 OD026553/OD/NIH HHS/United States
- OT2 OD023205/OD/NIH HHS/United States
- OT2 OD025276/OD/NIH HHS/United States
- OT2 OD026557/OD/NIH HHS/United States
- OT2 OD026554/OD/NIH HHS/United States
- U24 OD023163/OD/NIH HHS/United States
- OT2 OD023206/OD/NIH HHS/United States
- U24 OD023176/OD/NIH HHS/United States
- OT2 OD026548/OD/NIH HHS/United States
- OT2 OD026549/OD/NIH HHS/United States
- R61 HL158941/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources